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This work shows the application of machine learning to predict current CD4 cell count of an HIV-positive 
patient using genome sequences, viral load and time. A regression model predicting actual CD4 cell 
counts and a classification model predicting if a patient’s CD4 cell count is less than 200 was built using 
a support vector machine and neural network. The most accurate regression and classification model 
took as input the viral load, time, and genome and produced a correlation of co-efficient of 0.9 and an 
accuracy of 95%, respectively, proving that a CD4 cell count measure may be accurately predicted using 
machine learning on genotype, viral load and time. 
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The current trend in patient healthcare is personalized 
medicine where treatment is individualized, rather than a 
response to set physical presentations. Thus, access and 
interpretation of personal patient information is vital, in 
order to provide a sustainable and useful medical service. 
The science of information systems, management and 
interpretation plays an important role in the continuity of 
care of patients. This is becoming more evident in the 
treatment of HIV/AIDS. In 2008, there were between 30 
and 36 million HIV-positive patients around the world. 
HIV/AIDS is the leading cause of death in sub-Saharan 
Africa (Campbell et al., 2008) and is currently the fastest 
growing epidemic in South Africa (Simon-Meyer et al., 
2002). Southern Africa continues to have the largest 
burden of HIV, with sub-Saharan Africa home to 67% of 
HIV-positive patients. The South African Department of 




*Corresponding author. E-mail: singhyashik@gmail.com. 
priorities in the country (Campbell et al., 2008). It is 
estimated that 50% of all new infections in sub-Saharan 
Africa are from South Africa (Giarelli et al., 2000), 
currently with 5.5 million confirmed cases of the disease 
(Rispel et al., 2009). 
HIV infection can be effectively managed with 
antiretroviral (ARV) drugs, but close monitoring of the 
disease progression is vital. Monitoring of the progression 
of the disease is made even more important due to the 
emergence of HIV drug resistance, especially in deve-
loping countries with limited resource. HIV drug resis-
tance refers to the inability of the ARV drug to reduce the 
viral reproduction rate sufficiently. Poor management of 
HIV drug resistance will lead to opportunistic infections 
that make treatment of HIV more difficult and even may 
lead to fatalities. The Health Systems Trust reported that 
almost 44% of all HIV positive patient deaths are due to 
AIDS defined conditions, which includes HIV drug resis-
tance and poor monitoring of virus progression (Health 
Systems Trust, 2011). Given enough time, drug resis-






mutation rates of HIV (Vercauteren and Vandamme, 
2006). 
Laboratory (Fahey et al., 1990; Moss et al., 1998) and 
clinical (Cahn et al., 1991; Montaner et al., 1992) markers 
of disease progression can monitor HIV infection. Com-
mon laboratory tests include viral load (measurement of 
HIV nucleic acid concentration), CD4 lymphocyte counts 
or CD4/CD8 ratio (quantitative measurement of particular 
lymphocyte cells that indicate the strength of the immune 
system), HIV p24 antigenaemia (p24 antigen count 
increases one to three weeks after initial infection and is 
present before HIV antibodies are formed), erythrocyte 
sedimentation rate (a non-specific marker of inflam-
mation), and serum-β-2-microglobulin because high 
concentrations are a good predictor of AIDS (Morfeldt-
maringnson et al., 2002). Common clinical markers of 
disease progression are weight loss, mucocutaneous 
manifestations, bacterial infections, chronic fever, chronic 
diarrhoea, herpes zoster, oral candidiasis, and pulmonary 
tuberculosis (Morgan et al., 2002). 
One of the best available surrogate markers for HIV 
progression is the use of CD4 cell count information (Post 
et al., 1996; Schechter et al., 1994). In developed coun-
tries, and areas where there is a low rate of HIV infection, 
CD4 cell count is recognized as a standard measure of 
immunodeficiency in HIV positive patients (Mwamburi et 
al., 2005). Although this is also standard of care in deve-
loping countries, the measurement of CD4 cell count 
requires many complex and expensive flow cytometric 
procedures which burden the minimal resources available 
(Schechter et al., 1994). There have been previous 
attempts to predict CD4 cell count information using 
cheaper chemical assays and even correlating a patient’s 
total lymphocyte count (TLC) with CD4 cell counts using 
logistic and linear regression (Schechter et al., 1994; 
Mwamburi et al., 2005).  
In developing countries, TLC may be used to make 
treatment decisions when CD4 cell count is not available 
and patients are symptomatic (Daka et al., 2008). Mac-
hine learning has been used as a prediction tool in many 
areas of medicine, including predicting ARV drugs. HIV 
positive patients are resistant [(Vercauteren and 
Vandamme, 2006) MRI segmentation for breast images] 
(Kannan et al., 2011) to platelet transfusion requirements 
for leukemia (Ho and Chang, 2011). Machine learning 
may also be used to predict CD4 cell count information. 
Machine learning is an artificial intelligence computer 
science technique that tries to find a mathematical model 
that map between inputs and outputs of a domain pro-
blem. There are two stages of using machine learning 
techniques. These are: creating the mathematical model 
by learning mappings between given input and output, 
secondly using the model to predict an output given 
unseen input.  
Wang et al. (2002) developed a prototype neural net-
work machine-learning algorithm on a small dataset, and 
predicted the viral load of HIV-positive patients from geno- 




genotype and treatment data with 75% accuracy. Larder 
et al. (2007) later created a genotype and treatment his-
tory based input neural network model that predicted viral 
load with 69% accuracy. Altmann et al. (2008) created a 
machine-learning algorithm that predicts a dichotomized 
virological response that is, success or failure of therapy, 
with 80% success. This was later changed by predicting 
the probability of treatment success (Altmann et al., 
2009) based on a degree of predicted HIV drug resis-
tance.  
These previous studies were based on predicting viral 
load or a dichotomized response. These are valuable in 
the treatment of HIV, however, most treatment guidelines 
in developing counties are based on CD4 guided mana-
gement of HIV. CD4 guided management of HIV has 
been described as well-tolerated and cost-saving 
(Ananworanich et al., 2005). CD4 guided treatment is a 
proven approach to long term management of HIV (Dyner 
et al., 2006).  
There has, however, been no computer model deve-
loped to predict current CD4 cell count. Singh and Mars 
(2010) describes a model that predicts how CD4 count 
may change in the future and also how ARV drugs may 
affect future changes in CD4 cell count. The model how-
ever, does not predict current CD4 count, and thus does 
not speak to the advantages of knowing how to allocate 
current recourse and how to manage patients at the 
current point in time.  
The aim of this study was to apply machine-learning 
techniques to produce a mathematical model that can 
predict a measure of CD4 cell count at an individual HIV-1 
positive patient level that is, an actual CD4 cell count or 
whether a patient’s CD4 cell count is less than 200. This 
amounts to using machine learning to create a regression 
and classification mathematical model, respectively. 
 
 




Separate patient datasets containing protease (PR) or reverse 
transcriptase (RT) genome sequences, CD4 cell counts or viral 
loads were obtained from the Stanford HIV drug resistance data-
base (http://hivdb.stanford.edu/). These de-identified datasets are 




PR genome sequences, CD4 cell count, viral load and the number 
of weeks from the baseline measure of CD4 cell count for each 
patient sample was determined by joining individual datasets using 
sample identifier (unique number that identifies a sample) and date. 
This was also done for the RT dataset, creating two datasets to 
apply the machine learning techniques on. The PR population 
dataset consisted of approximately 4,500 data elements, while the 
RT population dataset contained approximately 2,500 sequences. 
Each protease sequence consisted of 99 amino acids from position 
1 to 99, and each reverse transcriptase sequence comprised of 201 
amino acids from position 40 to 240. The sequences were 
processed such that at any  position, 1 represented  an  amino  acid 
 
















mutation and a 0 represented no mutation. The PR and RT data-
sets were further processed to reduce the number of amino acid 
positions that would be used for learning and testing. The number 
of mutations that occurred in the entire dataset at each position was 
calculated. All positions were the total number of mutations was 
less than 5% were removed. This resulted in the PR dataset having 
genome sequence data in 31 positions, while the RT dataset had 
data in 47 positions. 200 random data elements were removed from 
each dataset and formed a testing set. Training was done on the 
remaining data elements of the PR and RT datasets. The distri-
butions of the change in CD4 cell counts found in the test, training, 
and PR and RT population datasets are shown in Figures 1 and 2. 
Since the distributions of the test, training and population datasets 
are similar, we can conclude that the training and testing datasets 
are representative of the RT and PR population datasets. 
 
Input of the machine learning algorithms 
 
Three different groups of inputs were created and each were fed 
into the machine learning algorithms separately, forming six models 
for regression and six for classification. These input groups were: 
input 1, consisted only of viral load; input 2, consisted of viral load 
and genome sequence; input 3, consisted of viral load, genome 
sequence and number of weeks the CD4 cell count was taken from 
baseline CD4 cell count and; input 4, consisted of genome 
sequence only. 
Output of the machine learning algorithms 
 
The output of the regression machine learning models was the 
actual CD4 cell count. For classification, the data elements were 
grouped into two categories, as shown in Equation 1. 
 
            (1) 
 
 
Machine learning techniques 
 
Two machine learning techniques were used to find a mapping 
between the three input groups and the measure of CD4 cell count. 
The first was a statistical technique called support vector machines 
(SVMs) and the other was a neural network (NN) which is a 
technique based on the structure of the human brain’s neuron. 
SVMs were chosen due to their ability to learn high dimension 
inputs and they are a robust learning method (Daka et al., 2008; 
Navia-Vazquez, 2007; Bugers, 1998). Neural networks (Draghici et 
al., 2003) are one of the most common machine learning algorithms 
that have proven to be valuable in many domain environments. 
 
Support vector machines 
 












space and then attempts to find linear relations in that space. SVMs 
have been described as having the properties of duality, ability to 
incorporate kernels, margin maximization, convexity, and sparse-
ness. The simplest possible SVM is one that learns data in linear 
space. This means that there must exist a linear separating hyper-
plane (H0) that completely separates the input space from its output 
space. This separating boundary divides the input space in such a 
way that all input space elements that lie on one side of the 
boundary have the output space value of +1, while those on the 
opposite side have the value -1. This separation is shown in Figure 
3.  
SVMs try to maximize the margin between (H0) and (H1), that is 
||W||. After incorporating the Wolf dual, Lagrangian multipliers and 
kernels (K(), which is used to convert a non-linear search space into 





Where, Imp is a user defined value that assigns the importance of 
an error, external stimuli called the bias (β), αi are Lagrangian 
multipliers, Xi is the input space, and yi is the output space for i = 1 
… number of data elements.  
SVMs solve regression by converting it into a classification 
problem. Assume that a SVM is trying to approximate a function y = 
f(x) with z = g(x). Thus, for any given x, if regression (f(x),g(x)) = 0 




0,                    ||f(x)-g(x)||< 
  (3) 




LibSVM (http://www.csie.ntu.edu.tw/~cjlin/libsvm/) was used to 
create the SVM model in this study. A radial base function kernel 
and a cost of 3000 were used. A cost of 3000 was chosen as it 





All neural networks contain an electronic representation of the 
human neuron. These networks use and interconnect these neu-
rons in various manners in order to perform learning. Similar to the 
dentrites attached to the axon of the human neuron, the electronic 
neuron has channels which transport input (α) into the core of the 
neuron. The electronic neuron has weights (ϖ) and an external 
stimuli called the bias (β). The electronic neurons may or may not 
fire, depending on the value (θ) of the product and summation of 
the inputs, weights and bias, and on the type of activation function 
(Ψ) that is used. Mathematically, a neuron can be described as 
shown in Equations 4 and 5. This study used a single layer, recur-
rent neural network with 8 neurons which was created using Neuro-
Solutions (http://www.neurosolutions.com/). 
 
         (4) 
 
             (5) 
 
 
Statistical analysis  
 
Pearson's correlation (r) was used to measure how closely the 
regression model correlates to known CD4 counts. The correlation 
was computed as shown in Equation 6. 
 
r 





   
(6) 
 
Where, n is the number of tuples in a dataset, Xi is the i
th
 desired 
CD4 cell count, Yi is the i
th
 predicted CD4 cell count, Sx and Sy are 
the standard deviations of the desired and predicted CD4 counts. 
Accuracy, sensitivity, specificity, positive predictive value and 
negative predictive value were used to determine how close the 
classification model predicted the known CD4 cell counts. Accuracy 
was defined as the percent of correct predictions. Sensitivity was 
calculated as the number of predicted patients whose CD4 cell 
counts were greater and equal to 200, compared to all patients 
whose CD4 cell counts were greater and equal to 200. Specificity 
was determined by calculating the number of predicted patients 
whose CD4 cell counts were less than 200 compared to all patients 
whose CD4 cell counts were less than 200. Positive predictive value 
is defined as the proportion of patients with CD4 cell counts less 
than 200 who are correctly diagnosed, similarly for negative pre-
dictive value. The best regression mathematical model was deter-
mined by comparing coefficient of correlations of all regression 
models using the Fisher-Z score. Multivariate random block analy-
sis of variance (RBD) was used to compare accuracy, sensitivity, 
specificity, positive predictive values and negative predictive values 





Accuracies,  sensitivities,  specificities, positive  predictive 
 




Table 1. Accuracy and regression results produced by support vector machines and neural networks. 
 
Dataset Type 





Acc Sen Spec PPV NPV Acc Sen Spec PPV NPV 
PR 
Input 1 61 64 73 64 73 0.51 78 28 84 64 54 0.41 
Input 2 89 89 89 87 91 0.76 78 31 72 53 51 0.19 
Input 3 87 81 91 86 88 0.77 75 42 73 61 56 0.19 
Input 4 71 70 71 59 80 0.6 79 40 81 68 58 0.42 
              
RT 
Input 1 74 60 79 59 79 0.52 80 91 77 57 91 0.43 
Input 2 91 86 94 89 92 0.90 88 48 84 75 62 0.51 
Input 3 95 94 92 86 97 0.85 83 63 77 73 68 0.39 
Input 4 81 78 82 63 90 0.55 80 46 82 72 60 0.46 
 




Table 2. Results of RBD analysis of variance (
a
P > 0.05, 
b
P < 0.05, 
c
P < 0.001). 
 




















Table 3. Post Hoc testing for differences in input and 
machine learning algorithms in terms of various measures 
(
a
P > 0.05; 
b
P < 0.05; 
c
P < 0.001). 
 
























value (PPV), nearest point problem (NPP) and the coeffi-
cient of correlation for the support vector machine and 
neural network models are shown in Table 1. Input 1 pro-
duced an average accuracy of 73%; input 2, an average 
accuracy of 86%; input 3, 85% and input 4, an average 
accuracy of 77%. The highest accuracies produced with 
SVMs were 95% for RT and nput 3, while neural net-
works achieved 88% with input 2 and RT. Multivariate 
random block design analysis of variance (RBD) was 
used to determine if the differences shown in Table 1 are 
statistically significant, taking into account the effects of 
the variance on the datasets, input groups and machine 
learning techniques.  
Random block design is a statistical theoretical frame-
work that is used to analyze variance. It is similar to a two 
factor fixed-fixed design, but is applied to datasets were 
there is only a single value for each factor. RBD was 
performed with machine learning techniques as the treat-
ment factor, input groups, protease and reverse transcrip-
tase genome datasets as blocks, and the accuracies, 
sensitivities, specificity, positive predictive value and 
negative predictive value as the dependent variables. 
These results are shown in Table 2. 
Duncan post hoc testing on the effect of the different 
machine learning algorithms on accuracy, specificity, 
PPV and NPV are shown in Table 3. Similarly, Duncan 
post hoc results for input groups are shown in Table 4 (1 
to 2 refers to comparing input 1 to input 2, 1 to 3 is 
comparing input 1 to input 3 and 2 to 3 comparing input 2 
to Input 3). Table 5 contains the results of the Fisher-Z 





The Fmachine and p values in Table 2 are less than the 
critical value at 95% confidence level for all of Pillai’s 
Trace, Wilks Lambda, Hoteling’s Trace and Roys’s Lar-
gest Root. Thus, there is a statistically significant 
difference between the two machine learning algorithms. 
Duncan post hoc tests (Table 3) indicate that there are 
statistical differences between the learning methods for 
accuracy, sensitivity, specificity, PPV and NPV. There is 
an 11% difference in accuracies between SVM’s and 
NN’s, taking into account all input groups. The higher 
overall accuracies, sensitivities, specificities, PPN and 
NPV across all input groups as a whole indicate that 
SVM’s outperform NN’s. 
The fact that SVM’s outperformed NN’s confirms the 
ability of SVM’s to better learn highly dimensional, com-
plex and non-separable data. Thus, when the input space 
dimensionality increased by adding genome data, SVM’s 
prediction improved. NN’s, on the other hand, does not 
learn high dimensional data well, thus learning was not 
improved much after adding genome data. Finput and p 
values, in Table 3 indicate that there is a statistically
 




Table 4. Ad Hoc to determine differences in input groups. 
 
Input Accuracy Sensitivity Specificity PPV NPV 
1-2 0.044 0.042 0.034 0.003 0.007 
1-3 0.036 0.042 0.034 0.003 0.006 
2-3 0.986 1.000 1.00 0.672 0.973 
1-4 0.008 0.009 0.007 0.002 0.009 
2-4 0.030 0.009 0.050 0.040 0.009 




Table 5. Fisher's Z score for comparing regression (
a
P > 0.05, 
b




























significant difference between the input groups. Post hoc 
testing (Table 4) indicates that, in terms of accuracy, all 
input groups were statistically different, except between 
input 2 and input 3. The same results are seen in sen-
sitivity, specificity and PPV.  
Taking into account accuracy, sensitivity, specificity, 
PPV, and NPV input 1 performed the worst. Input 4 
produced a better prediction model input space. These 
results indicate the importance of genome data in the 
prediction model. The prediction results were improved 
by using input 2 and input 3 (that is, adding viral load). 
This is due to the fact that the viral load is indicative of 
the ARV drugs being administered. In order to produce a 
good prediction model, it is vital that the current ARV 
treatment is taken into account.  
There is no statistically significant difference between 
input 2 and input 3. The number of weeks from the treat-
ment baseline does not seem to improve classification. 
This may be due to the fact that the effect of the ARV 
over the time duration is reflected by the mutations in the 
genome. P values in Table 5, indicates that there is a 
significant statistical difference between the ability of 
SVM’s to predict CD4 cell count than NNs (except for RT 
input 1). This again, proves the superior ability of SVM to 
learn highly complex data.  
The previous studies discussed, predicted treatment 
outcomes in terms of viral load, total lymphocyte count, or 
success or failure of treatment. However CD4 guided 
treatment important in the management of HIV (Dyner et 
al., 2006) is even recognized as the gold standard for 
treatment (Obirikorang et al., 2012). This study con-
tributes by allowing the prediction of current CD4 cell 
count that may be used when managing HIV through CD4 
cell count guided treatment. It has been suggested that 
CD4 guided treatment should be included in the decision 
making process of complex HIV cases where there is 
clinical benefit with failing treatment but with immunologic 
benefits where CD4 count > 350 cells/mm
3
 (Dyner et al., 
2006). Thus, the ability of this tool to predict current CD4 
cell count will be invaluable when one needs constant 
monitoring of the patients CD4 cell count. 
This tool is also beneficial in terms of resource allo-
cation although standard of care that continuously moni-
tor CD4 cell counts are resource intensive. Instead, one 
may predict CD4 cell count over a longer period of time 
with a single genome. Only if the algorithm predicts a low 
CD4 count, will the patient be sent for a laboratory CD4 





Results obtained from this study indicate that a measure-
ment of CD4 cell count can be successfully predicted 
using machine learning. Actual CD4 cell counts and pre-
dicting if a patient’s CD4 cell count is less than 200 is 
possible using protease and reverse transcriptase 
genomes, viral load and number of weeks from baseline 
measure. Support vector machines were shown to out 
perform neural networks, both in predicting CD4 cell count 
and if the CD4 cell counts are less than 200.  
 




Genome data were also shown to improve the prediction 
abilities of the machine learning algorithms.  
To the knowledge of the authors, predicting CD4 cell 
counts using protease and reverse transcriptase genomes, 
viral load and number of weeks from baseline measure is 
novel. This study is the first objective of a project trying to 
predict a patient’s future CD4 cell count trend when there 
is a treatment change. Future work will include replacing 
the viral load measurement in the predictive model with 
actual therapy information and adding more classification 
output categories. This will aid physicians in guiding HIV 
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